EUCTR2019-001188-58-SE进行中（未招募）1 期
The effect of anti-IL17 in new-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial - I-DIT
Göteborgs Universitet0 个研究点目标入组 127 人开始时间: 2020年9月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 127
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for inclusion in the study have to fulfil all of the following criteria:
- •Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations before trial activities are begun.
- •Must be willing and capable of taking the study drugs and meet for tests and follow up as described.
- •Diagnosed Type 1 Diabetes (E10.9) within 100 days.
- •First injection of insulin maximum 100 days prior to screening. If age 36-45 years, a current insulin regimen of both basal and prandial insulin or alternately use of an insulin pump should exist.
- •Aged 18-45 years old.
- •Presence of antibodies at clinical practice or at screening to at least one of the following antigens: insulin/IAA, GAD-65, IA-2 and ZnT8.
- •Remaining stimulated peak C–peptide = 0.20 nmol/L. If age 36-45 years, peak C-peptide should be <2.0 nmol/L.
- •Male subjects agree to use a reliable method of birth control during the study.
- •Female subjects:
- •Participants of childbearing age or childbearing potential who are sexually active who test negative for pregnancy must be counseled and agree to use either 1 highly effective method of contraception or 2 acceptable methods of contraception combined for the duration of the study and for at least 12 weeks following the last dose of study drug or remain abstinent during the study and for at least 12 weeks following the last dose of study drug.
- •If the highly effective contraceptive methods are contraindicated or strictly declined by patient, acceptable birth control methods may be considered. These may include combination of both of the following methods:
- •oMale or female condom with spermicide
- •oCap, diaphragm, or sponge with spermicide
- •1.Highly effective methods of contraception (use 1 form):
- •ocombined oral contraceptive pill and mini-pill
- •oimplantable contraceptives
- •oinjectable contraceptives (such as Depo-Provera®)
- •ointrauterine device (such as Mirena® and ParaGard®)
- •ocontraceptive patch—ONLY women <198 pounds or 90 kg
- •oabstinence from sex
- •ovasectomy—for men in clinical studies
- •2.Effective methods of contraception (use 2 forms combined)
- •omale condom with spermicide
- •ofemale condom with spermicide
- •odiaphragm with spermicide
- •ocervical sponge
- •ocervical cap with spermicide
- •Females who are not of childbearing potential include those who have undergone or who have:
- •ofemale sterilization
- •ohysterectomy
- •oMüllerian agenesis (Mayer–Rokitansky–Küster–Hauser syndrome [also referred to ascongenital absence of the uterus and vagina])
- •Females who are not of childbearing potential include those who have undergone or who have:
- •ofemale sterilization
- •ohysterectomy
- •oMüllerian agenesis (Mayer–Rokitansky–Küster–Hauser syndrome [also referred to ascongenital absence of the uterus and vagina])
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 127
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects fulfilling any of the following criteria are not eligible for inclusion in this study:
- •Contraindications to Ixekizumab.
- •Treatment with any oral or injected glucose-lowering agents other than insulin.
- •A history of haemolytic anaemia or significantly abnormal haematology/coagulation results at screening.
- •Participation in other clinical trials with a new chemical entity within the previous 3 months.
- •Subjects with severe obesity (BMI >35 kg/m2 if age 18-35 years and BMI >30 kg/m2 if age 36-45), psoriasis, psoriasis arthritis and axial spondylarthrosis, except celiac disease and hypothyroidism which do not need to be excluded for.
- •Active serious or chronic infections (ie: in case patient had a serious infection (eg pneumonia, cellulitis), has been hospitalized, has received intravenous antibiotics for an infection within 12 weeks prior to screening visit, had a serious bone or joint infection within 24 weeks before screening visit, has ever had an infection of an artificial joint
- •Known immunodeficiency or patient is immunocompromised to an extent that participation in the study would pose and unacceptable risk to the patient
- •Active or latent tuberculosis
- •HIV or active hepatitis B or C
- •Active or recurrent fungal infection
- •Subjects with myocardial infarction, stroke, unstable angina or heart failure last 6 months
- •Current clinically significant cardiac arrhythmias as verified by ECG
- •Planned surgery during the treatment period of the study (except minor surgery on skin lesions, e.g., nevus)
- •For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 3- months after discontinuation.
- •For male subjects: intent to procreate during the duration of the study or within 3 months after discontinuation or unwillingness of their partner to use effective contraceptive measures for the duration of the study and 4 months after discontinuation.
- •Any history of malignancy the last 5 years except for completely resected squamous or basal cell carcinoma of the skin.
- •Administration of live attenuated vaccine(s) (LAV) within 2 months of enrolment. Or intended use of LAV during the treatment period.
- •The investigator judges that the clinical diagnosis of T1D set is incorrect or uncertain (needs to be confirmed by discussion with experienced diabetologist if excluding due to this criterion)
- •Allergy against ingredients of the investigational products.
- •Known allergy or hypersensitivity to any biologic therapy (active substance or excipients) that would pose an unacceptable risk to the patient if participating in the study
- •Presence of serious disease or condition, which in the opinion of the investigator makes the patient non-eligible for the study.
- •Liver injury criteria: patients with active hepatobiliary diseases or at screening having alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal (>2.5 x ULN)
- •Laboratory abnormalities at screening:
- •a.Neutrophil count < 1,500 cells/ µL (=1,5 *109 cells/ L)
- •b.Platelet count < 100,000 cells/ µL (= 100 *109 cells/ L)
- •c.Hemoglobin < 8.5 g/dL (= <85 g/L) (males) and <8g/dL (= <80 g/L) (women)
研究者
相似试验
进行中（未招募）
2 期
Ixekizumab Diabetes Intervention Trial (I-DIT)Type1 Diabetes MellitusNCT04589325Göteborg University127
已完成
2 期
Mechanism of action study of anti-IL17 therapy in spondyloarthritis: impact on cellular and molecular pathways of synovial inflammation and tissue remodelling.ankylosing spondylitisSpondylarthropathy1000381610023213NL-OMON41538Academisch Medisch Centrum20
进行中（未招募）
不适用
Mechanism of action study of anti-IL17 treatment in spondyloarthritis.MedDRA version: 16.1Level: LLTClassification code 10032155Term: Other inflammatory spondylopathiesSystem Organ Class: 100000004859MedDRA version: 16.1Level: LLTClassification code 10070759Term: SpondylopathySystem Organ Class: 100000004859SpondyloarthritisEUCTR2013-002709-79-NLAcademic Medical Center, Department of Rheumatology
已完成
2 期
The effect of lixisenatide in type 1 diabetesTopic: DiabetesSubtopic: Type 1Disease: Diabetic ControlNutritional, Metabolic, EndocrineISRCTN00290196niversity of Oxford (UK)27
进行中（未招募）
1 期
The LIXI trial is aiming to recruit individuals with type 1 diabetes who are using insulin to control their disease. The trial is investigating whether a daily injection of a newly-licenced drug called lixisenatide, taken alongside a person's usual insulin medication can improve blood sugar levels after meals.MedDRA version: 14.1 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersType 1 diabetes mellitusEUCTR2013-002259-14-GBniversity of Oxford27